MDNA vs. AIM, IPA, FRX, ITH, APM, GXE, CRDL, GPH, EQ, and WMD
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Aimia (AIM), ImmunoPrecise Antibodies (IPA), Fennec Pharmaceuticals (FRX), International Tower Hill Mines (ITH), Andean Precious Metals (APM), Gear Energy (GXE), Cardiol Therapeutics (CRDL), Graphite One (GPH), EQ (EQ), and WeedMD (WMD). These companies are all part of the "pharmaceutical products" industry.
Medicenna Therapeutics vs.
Medicenna Therapeutics (TSE:MDNA) and Aimia (TSE:AIM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.
Aimia has a consensus price target of C$4.00, indicating a potential upside of 61.94%. Given Aimia's stronger consensus rating and higher probable upside, analysts clearly believe Aimia is more favorable than Medicenna Therapeutics.
13.0% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of Aimia shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aimia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aimia has a net margin of -16.96% compared to Medicenna Therapeutics' net margin of -533,640.00%. Aimia's return on equity of -14.38% beat Medicenna Therapeutics' return on equity.
In the previous week, Aimia had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 1 mentions for Aimia and 0 mentions for Medicenna Therapeutics. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Aimia'saverage media sentiment score.
Medicenna Therapeutics has higher earnings, but lower revenue than Aimia. Aimia is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aimia received 302 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. However, 68.22% of users gave Medicenna Therapeutics an outperform vote while only 54.24% of users gave Aimia an outperform vote.
Medicenna Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Aimia has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Summary
Aimia beats Medicenna Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
This page (TSE:MDNA) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy MDNA Stock Free MDNA Stock Alerts